Coexistence of P190 and P210 BCR/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib

详细信息    查看全文

• 作者：Zhao Junmei ; Yu Fengkuan ; Song Yongping ; Fang Baijun ; Liu Yuzhang ; Liu Lina…
• 关键词：Chronic myeloid leukemia ; BCR/ABL ; Rsistance ; Ematinib
• 刊名：SpringerPlus
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：4
• 期：1
• 全文大小：616KB
• 参考文献：Agirre X, Fontalba A, Andreu EJ, Odero MD, Larrayoz MJ, Montiel C, Calasanz MJ, Fernandez-Luna JL, Prosper F (2003) Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response. Haematologica 88(12):1425鈥?426
  Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel A, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M (1983) Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306(5940):277鈥?80CrossRef
  Chissoe SL, Bodenteich A, Wang YF, Wang YP, Burian D, Clifton SW, Crabtree J, Freeman A, Iyer K, Jian L (1995) Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics 27(1):67鈥?2CrossRef
  Costello RT, Gabert J, Brunel V, Sainty D, Arnoulet C, Mozziconacci MJ, Camerlo J, Perret C, Gastaut JA, Bouabdallah R (1995) Minor breakpoint cluster region (m-BCR) positive chronic myeloid leukaemia with an acute lymphoblastic leukaemia onset: a case report. Br J Haematol 91(2):428鈥?30CrossRef
  Druker BJ (2002) Perspectives on the development of a molecularly targeted agent. Cancer Cell 1(1):31鈥?6CrossRef
  Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, Pioltelli P, Pogliani E, Corneo G, Formelli F, D'Incalci M (2000) Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92(20):1641鈥?650CrossRef
  Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L (2003) Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 4(2):75鈥?5CrossRef
  Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16(11):2190鈥?196CrossRef
  Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, Zhou X, Luthra R, Garcia-Manero G, Giles F, Rios MB, Verstovsek S, Cortes J (2006) Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20(10):1767鈥?773CrossRef
  Melo JV (1996) The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88(7):2375鈥?384
  Savage DG, Antman KH (2002) Imatinib mesylate鈥揳 new oral targeted therapy. N Engl J Med 346(9):683鈥?93CrossRef
  Shah N, Oseth L, LeBien TW (1998) Development of a model for evaluating the interaction between human pre-B acute lymphoblastic leukemic cells and the bone marrow stromal cell microenvironment. Blood 92(10):3817鈥?828
  Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Castagnetti F, Testoni N, Luatti S, de Vivo A, Cilloni D, Izzo B, Fava M, Abruzzese E, Alberti D, Pane F, Saglio G, Baccarani M (2005) ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 23(18):4100鈥?109CrossRef
  Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, Wurster-Hill DH, Sobol RE, Schiffer C, Bloomfield CD (1992) Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 80(12):2983鈥?990
  Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, Stoffregen EP, McWeeney S, Kovacs I, Park B, Druker BJ, Deininger MW (2005) High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 106(6):2128鈥?137CrossRef
  Yamaguchi H, Inokuchi K, Shinohara T, Dan K (1998) Extramedullary presentation of chronic myelogenous leukemia with p190 BCR/ABL transcripts. Cancer Genet Cytogenet 102(1):74鈥?7CrossRef
  
• 作者单位：Zhao Junmei (1)
  Yu Fengkuan (1)
  Song Yongping (1)
  Fang Baijun (1)
  Liu Yuzhang (1)
  Liu Lina (1)
  Zhang Qinglan (1)
  
  1. Henan Key Lab of Experimental Haematology, Henan Institute of Haematology, Henan Tumor Hospital affiliated to Zhengzhou University, 127 Dongming Road, Zhengzhou, Henan Province, 450008, China
  
• 刊物类别：Science, general;
• 刊物主题：Science, general;
• 出版者：Springer International Publishing
• ISSN：2193-1801

文摘

Introduction Philadelphia chromosome (Ph) is a hallmark of chronic myeloid leukemia (CML), which exists in more than 90% CML and in 3% to 40% acute lymphoblastic leukemia (ALL).